Immunome Stock Alpha and Beta Analysis

IMNM Stock  USD 13.55  0.08  0.59%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Immunome. It also helps investors analyze the systematic and unsystematic risks associated with investing in Immunome over a specified time horizon. Remember, high Immunome's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Immunome's market risk premium analysis include:
Beta
2.14
Alpha
(0.38)
Risk
4.76
Sharpe Ratio
0.011
Expected Return
0.0523
Please note that although Immunome alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Immunome did 0.38  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Immunome stock's relative risk over its benchmark. Immunome has a beta of 2.14  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immunome will likely underperform. At this time, Immunome's Book Value Per Share is very stable compared to the past year. As of the 30th of November 2024, Tangible Book Value Per Share is likely to grow to 6.34, while Enterprise Value Over EBITDA is likely to drop (4.28).

Enterprise Value

121.06 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Immunome Backtesting, Immunome Valuation, Immunome Correlation, Immunome Hype Analysis, Immunome Volatility, Immunome History and analyze Immunome Performance.
To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.

Immunome Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Immunome market risk premium is the additional return an investor will receive from holding Immunome long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Immunome. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Immunome's performance over market.
α-0.38   β2.14

Immunome expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Immunome's Buy-and-hold return. Our buy-and-hold chart shows how Immunome performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Immunome Market Price Analysis

Market price analysis indicators help investors to evaluate how Immunome stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Immunome shares will generate the highest return on investment. By understating and applying Immunome stock market price indicators, traders can identify Immunome position entry and exit signals to maximize returns.

Immunome Return and Market Media

The median price of Immunome for the period between Sun, Sep 1, 2024 and Sat, Nov 30, 2024 is 12.97 with a coefficient of variation of 13.0. The daily time series for the period is distributed with a sample standard deviation of 1.68, arithmetic mean of 12.96, and mean deviation of 1.37. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Disposition of 14380 shares by Max Rosett of Immunome at 16.01 subject to Rule 16b-3
09/19/2024
2
Insider Selling Immunome, Inc. CFO Sells 230,223.80 in Stock
09/23/2024
3
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635
11/01/2024
4
Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference
11/05/2024
5
FMR LLCs Strategic Acquisition of Immunome Inc Shares
11/13/2024
6
Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc
11/15/2024
7
Acquisition by Clay Siegall of 33943 shares of Immunome at 9.7787 subject to Rule 16b-3
11/22/2024
8
Insider Buying Robert Lechleider Acquires Shares of Immunome Inc
11/25/2024
9
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
11/27/2024
10
Insider Trading
11/29/2024

About Immunome Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Immunome or other stocks. Alpha measures the amount that position in Immunome has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2021 2022 2023 2024 (projected)
Current Ratio5.823.096.634.38
Net Debt To EBITDA2.040.553.433.6

Immunome Upcoming Company Events

As portrayed in its financial statements, the presentation of Immunome's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immunome's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Immunome's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Immunome. Please utilize our Beneish M Score to check the likelihood of Immunome's management manipulating its earnings.
21st of March 2024
Upcoming Quarterly Report
View
3rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Immunome

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Immunome is a strong investment it is important to analyze Immunome's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immunome's future performance. For an informed investment choice regarding Immunome Stock, refer to the following important reports:
Check out Immunome Backtesting, Immunome Valuation, Immunome Correlation, Immunome Hype Analysis, Immunome Volatility, Immunome History and analyze Immunome Performance.
To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Immunome technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Immunome technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Immunome trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...